Evaluation of arterial hypertension control and treatment in daily practice of family physicians

Žaneta Petrulionienė¹², Daiva Asta Apanavičienė³

¹Center of Cardiology and Angiology, Vilnius University Hospital Santariskių klinikos,
²Department of Cardiovascular Medicine, Faculty of Medicine, Vilnius University, ³“Sanofi-Aventis Lietuva,” Lithuania

Key words: arterial hypertension; blood pressure control; antihypertensive drugs.

Summary. The objective of this study was to evaluate the percentage of patients with primary arterial hypertension treated with antihypertensive drug(s), who achieved target arterial blood pressure (ABP), and to compare the characteristics of patients with controlled and uncontrolled ABP, their current treatment, and treatment modifications.

Material and methods. A total of 429 18–80-year-old patients with primary arterial hypertension treated for ≥1 year participated in this study. General practitioners collected data on patients’ demographic and clinical characteristics, current treatment for primary arterial hypertension, and treatment modifications.

Results. According to physicians, 45.4% of patients achieved target ABP levels. Adequately controlled ABP was documented more often in the group of low and moderate cardiovascular risk than in high- and very high-risk group (n=141, 62.9% versus n=54, 26.3%; P<0.0001). Based on ABP measurements, 160 (37.3%) patients had ABP of <140/90 mm Hg. The majority of patients were treated with a combination of two (n=153, 35.7%) to three (n=144, 33.6%) antihypertensive drugs. Patients with uncontrolled ABP more frequently than patients with controlled ABP were given combination therapy. Treatment was not modified in 37.8% (n=162) of patients, more commonly in those with controlled ABP.

Conclusions. The level of hypertension control in study population was far from optimal, especially in the group of patients at high- and very high-risk where target ABP was lower. Almost 12% of patients with uncontrolled ABP were still undergoing monotherapy, whereas 16% of patients were not recommended any modifications of antihypertensive treatment despite their ABP was not controlled.

Introduction

Arterial hypertension is one of the main risk factors of atherosclerosis. High blood pressure increases the risk of coronary heart disease, stroke, peripheral artery disease, and heart failure (1). Arterial hypertension is diagnosed for almost every second Lithuanian adult: in 1999, arterial hypertension was diagnosed for 59.3% of men aged 25–64 years and 42.1% of women of the same age (2).

Despite a number of medicines, efficacy of which was proved in clinical trials, comprehensive treatment recommendations, and the increasing amount of knowledge related to the pathophysiology of hypertension, the arterial blood pressure (ABP) control is still not adequate over the world. The results of epidemiological studies indicate that less than half of patients suffering from increased blood pressure are treated systemically in advanced industrial countries; in addition, the percentage of patients constantly receiving an effective treatment is only 15–20% (3). The main reasons of such inadequate results are related to patients (noncompliance with the treatment regime, poor toleration of drugs) and physicians (noncompliance with the accepted treatment recommendations, absence of complex and nonpharmaceutical treatment) (4–7). The effective antihypertensive treatment reduces the risk of stroke, coronary heart disease, and cardiovascular death by 38%, 16%, and 21%, respectively (3). Additionally, effective treatment improves quality of life in patients who received it (8).

Lately, there are limited data published in Lithuania regarding blood pressure control of the patients who underwent treatment. The objective of this study was to evaluate the percentage of patients with primary arterial hypertension and treated with antihypertensive drugs, who achieved target blood pressure defined in the Lithuanian guidelines on diagnostics and outpatient treatment of arterial hypertension (9) and to compare the characteristics of...
patients who achieved and did not achieve the target blood pressure, their current treatment, and recommended treatment modifications.

Material and methods
The permission to carry out this study was obtained from the Lithuanian Bioethics Committee. This epidemiologic trial was conducted in accordance with the ethical principles outlined in the Helsinki declaration accepted by the 18th General Assembly of the World Medical Association (Helsinki, 1964) and in the subsequent amendments of the declaration (1975, 1983).

The study was carried out during the period of November 2006 to January 2007. In order to see the real reflection of blood pressure control among hypertensive patients from various regions of Lithuania (both urban and rural population), randomly chosen physicians were asked to participate in the study. A total of 24 general practitioners from the cities of Klaipėda, Šilutė, Plungė, Telšiai, Škudinės, Šiauliai, Akmenė, Panevėžys, Kaunas, Šakiai, Klaipėda, Širvintos, and Vilnius and regions participated in this study. Each physician was allowed to include up to 15 patients. Every third patient who came for a regular visit was asked to participate in this trial. If the patient did not meet the inclusion criteria, the next one was asked to participate in this trial. A total of 429 patients meeting inclusion criteria, the next one was asked to participate in this study. In a single visit, physicians collected information about age, sex, duration of arterial hypertension, concomitant diseases, and risk factors, antihypertensive agents used, measured ABP and heart rate. Demographic and clinical data were recorded in accordance with patients’ medical records. There were no specific laboratory tests carried out. Only ABP and heart rate were measured on the visit day. ABP was measured using a calibrated mechanic aneroid sphygmomanometer (manufacturer Rudolf Riester GmbH, Big Ben® model) after 5-minute rest; the test was performed in a sitting position. ABP was measured twice for each patient. In case of the difference in SBP and/or DBP by 10 mm Hg or more during the first two measurements, the physician was required to perform the third ABP measuring. The average value calculated from these measurements was entered into the data collection forms. Heart rate (beats in 1 minute) was also recorded after rest in a sitting position.

Risk factors of the patients were evaluated based on the following diagnostic criteria according to the European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension (10):

- Microalbuminuria: albumin concentration of >30 mg/24 h (corresponds to >20 μg/min in the morning urine sample or albumin-creatinine ratio of >22 mg/g for men and >31 mg/g for women in the random urine sample, or >20 mg/L determined using a reagent strip).
- Dyslipidemia: total cholesterol concentration of >6.5 mmol/L (250 mg/dL) or low-density lipoprotein cholesterol concentration of >4.0 mmol/L (155 mg/dL) or high-density lipoprotein cholesterol concentration of <1.0 mmol/L (40 mg/dL) for men and <1.2 mmol/L (48 mg/dL) for women.
- Obesity: body mass index (BMI) of ≥30 kg/m².
- Smoking.

Patients were assigned by physicians to the groups of low or moderate risk for cardiovascular diseases or to high or very high risk for cardiovascular diseases. Evaluation of patients’ risk was based on the Lithuanian guidelines on diagnostics and outpatient treatment of arterial hypertension (9) and data in the medical records regarding the risk factors, damages of target-organs, and diagnosis of concomitant diseases. Based on the criteria outlined in these guidelines, patients classified in the low or moderate cardiovascular risk groups had a high normal ABP or grade 1 hypertension plus 1–3 risk factors (except resistance to insulin and/or diabetes). Patients at high or very high cardiovascular risk had only grade 2 hypertension or grade 1 or 2 hypertension and 3 risk factors (resistance to insulin, intolerance of glucose or diabetes was sufficient) and/or damages of target-organs caused by arterial hypertension and/or concomitant clinical disorders aggravating the course of hypertension or complicating its treatment. Following the evaluation of the patients’ cardiovascular risk, physicians were required to assign them to one of the target ABP groups (<140/90 mm Hg in case of low and moderate risk, and <135/85–125/75 mm Hg in case of high and very high risk), to assess whether the target ABP was achieved or not, and to prescribe recommendations for a further treatment. ABP control was considered sufficient for the patients who achieved (based on physician’s records) the target ABP. ABP control was considered insufficient for the patients who did not achieve (based on physician’s records) the target ABP.

All information was registered anonymously into the standard data collection forms. The descriptive statistical analysis was carried out. The frequency tables were prepared for the categorical variables. Descriptive statistical parameters (average, median, minimal value, maximal value, standard deviation, 5% and 95% percentiles) were calculated for the continuous variables. Statistical differences were evaluated using the chi-square or Fisher’s exact test for categorical variables and Stu-
dent’s *t* test for continuous variables. Statistical differences were interpreted using a 5% significance level (two-sided). Statistical analysis was performed using the software SAS 9.1.2.

**Results**

A total of 429 patients suffering from essential arterial hypertension were enrolled into the study. There were 125 (29.3%) men and 301 (70.7%) women (gender of 3 patients was not indicated). The mean age of the patients was 61.7 years (SD, 10.7 years). Comparing men and women, there was no difference in the mean age (60.2 [SD, 11.6] and 62.3 [SD, 10.2] years, respectively) and mean ABP (143.3 [18.1]/87.3 [12.0] mm Hg and 144.2 [18.4]/85.2 [10.2] mm Hg, respectively). The mean duration of arterial hypertension of the patients was 12.7 years (SD, 9.1).

In accordance with the Lithuanian guidelines on diagnostics and outpatient treatment of arterial hypertension (8), 224 (52.2%) patients were assigned to the low or moderate cardiovascular risk group, and 205 (47.8%) patients to the high- and very high-risk group. There were more men than women in the high- and very high-risk group (53.6% and 45.5%, respectively), but the difference was not significant (*P* >0.05).

Based on physicians’ evaluation, almost half of the patients (45.4%) achieved the proposed target ABP. In the low- and moderate-risk group, the target ABP (<140/90 mm Hg) was achieved in 141 (62.9%) patients, whereas in the high- and very high-risk group, the target ABP (<135/85–125/75 mm Hg) was achieved only in 54 (26.3%) patients (*P*<0.0001). The mean blood pressure of the patients was lower in the low- and moderate-risk group than those in the high- and very high-risk group (140.1 [16.4]/83.8 [9.3] mm Hg and 148.1 [19.2]/87.9 [11.9] mm Hg, respectively; *P*<0.0001). The proportion of men and women who achieved the target ABP was similar in different cardiovascular risk groups: the target ABP was achieved by 36 (62.1%) men and 103 (62.8%) women from the low- and moderate-risk group and by 19 (28.4%) men and 35 (25.6%) women from high- and very high-risk group.

Based on measurements of blood pressure, ABP was appropriately controlled (<140/90 mm Hg) in 160 (37.3%) patients. The distribution of patients by different arterial blood pressure measured during the visit is presented in Fig. 17.

All the patients who participated in this study were given antihypertensive agents at least for 1 year. Angiotensin-converting enzyme (ACE) inhibitors were most frequently prescribed drugs; 323 (75.3%) patients were given ACE inhibitors. Many patients used β-blockers (n=262, 61.1%), diuretics (n=204, 47.6%), and calcium channel block-
### Table 1. Clinical characteristics of patients who achieved and did not achieve target blood pressure

| Characteristic                             | Patients who achieved target blood pressure (n=195) | Patients who did not achieve target blood pressure (n=234) |
|-------------------------------------------|----------------------------------------------------|----------------------------------------------------------|
| Age, mean (SD), years                     | 61.0 (10.8)                                        | 62.2 (10.6)                                               |
| Age ≥65 years                             | 84 (43.1)                                          | 102 (43.6)                                               |
| Systolic blood pressure, mean (SD), mm Hg | 129.5 (7.5)                                        | 155.9 (15.7)*                                            |
| Diastolic blood pressure, mean (SD), mm Hg| 78.8 (6.8)                                         | 91.6 (10.1)*                                             |
| Low and moderate risk                     | 141 (72.3)                                         | 83 (35.5)*                                               |
| High and very high risk                   | 54 (27.7)                                          | 151 (64.5)*                                              |
| No concomitant diseases                   | 89 (45.6)                                          | 57 (24.4)*                                               |
| More than one concomitant disease         | 65 (33.3)                                          | 113 (48.3)*                                              |
| Concomitant diseases                      |                                                    |                                                          |
| Diabetes mellitus                         | 15 (7.7)                                           | 35 (14.9)*                                               |
| Diabetic nephropathy                      | 3 (1.5)                                            | 11 (4.7)                                                 |
| Coronary heart disease                    | 74 (37.9)                                          | 127 (54.3)*                                              |
| Peripheral artery disease                 | 23 (11.8)                                          | 30 (12.8)                                                |
| Heart failure                             | 54 (27.7)                                          | 114 (48.7)*                                              |
| History of atrial fibrillation            | 20 (10.3)                                          | 27 (11.5)                                                |
| History of ischemic stroke                | 10 (5.1)                                           | 15 (6.4)                                                 |
| History of myocardial infarction          | 11 (5.6)                                           | 16 (6.8)                                                 |
| No risk factors                           | 40 (20.5)                                          | 33 (14.1)                                                |
| One risk factor                           | 81 (41.5)                                          | 79 (33.8)                                                |
| More than one risk factor                 | 74 (37.9)                                          | 122 (52.1)*                                              |
| Risk factors                              |                                                    |                                                          |
| Microalbuminuria                          | 1 (0.5)                                            | 6 (2.6)                                                  |
| Metabolic syndrome                        | 26 (13.3)                                          | 52 (22.2)*                                               |
| Dyslipidemia                              | 102 (52.3)                                         | 131 (55.9)                                               |
| Obesity                                   | 90 (46.1)                                          | 150 (64.1)*                                              |
| Smoking                                   | 20 (10.3)                                          | 27 (11.5)                                                |
| Other                                     | 5 (2.6)                                            | 1 (0.4)                                                  |

Values are number (percentage) unless otherwise indicated. *P<0.05.

### Table 2. Antihypertensive drugs used by patients who achieved and did not achieve the target blood pressure, and recommendations for treatment modifications

| Antihypertensive drugs and recommendations for treatment modifications | Patients who achieved target blood pressure (n=195) | Patients who did not achieve target blood pressure (n=234) |
|------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------|
| Antihypertensive therapy                                                |                                                    |                                                          |
| 1 antihypertensive drug                                                | 40 (20.5)                                          | 28 (11.9)*                                               |
| ≥2 antihypertensive drugs                                              | 155 (79.5)                                         | 206 (88.0)*                                              |
| Antihypertensive drugs                                                 |                                                    |                                                          |
| Diuretics                                                              | 73 (37.4)                                          | 131 (55.9)*                                              |
| Calcium channel blockers                                               | 59 (30.3)                                          | 96 (41.0)*                                               |
| α-Blockers                                                             | 15 (7.7)                                           | 21 (8.9)                                                 |
| β-Blockers                                                             | 118 (60.5)                                         | 144 (61.5)                                               |
| ACE inhibitors                                                         | 144 (73.8)                                         | 179 (76.5)                                               |
| Angiotensin receptor blockers                                          | 21 (10.8)                                          | 30 (12.8)                                                |
| Other antihypertensive drugs                                           | 16 (8.2)                                           | 23 (9.8)                                                 |

Recommendations for treatment modification

| Recommendations for treatment modification                              |                                                    |                                                          |
|-----------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------------|
| Nonpharmacologic measures                                             | 66 (33.8)                                          | 140 (59.8)*                                              |
| Only pharmacologic measures                                           | 58 (29.7)                                          | 48 (20.5)*                                               |
| Increase of the dose of the used drug                                 | 4 (2.0)                                            | 70 (29.9)*                                               |
| Administration of an additional drug                                  | 5 (2.6)                                            | 72 (30.1)*                                               |
| Change of the used drug                                               | 0 (0.0)                                            | 20 (8.6)                                                 |
| Treatment was not changed                                             | 125 (64.1)                                         | 37 (15.8)*                                               |

ACE, angiotensin-converting enzyme. Values are number (percentage). *P<0.05.
target ABP, only nonpharmacologic measures were recommended, whereas for the patients who did not achieve target ABP, usually nonpharmacologic recommendations were combined with an increased dose of the used drug or with administration of an additional drug (Table 2). Physicians did not change the treatment for almost 16% of the patients who did not achieve target ABP.

**Discussion**

The aim of this study was to evaluate the level of blood pressure control in patients treated with antihypertensive drugs. Based on evaluation of general practitioners, almost half (45.4%) of 429 patients suffering and treated for hypertension achieved target ABP (<140/90 mm Hg) in patients at low and moderate cardiovascular risk and <135/85–125/75 mm Hg in patients at high and very high cardiovascular risk. A higher proportion of patients (62.9%) achieved target ABP in the low- and moderate-risk group than those in the high- and very high-risk group (26.3%). Based on the values of blood pressure measured during the study, 37.3% of patients had ABP of <140/90 mm Hg.

Epidemiological studies performed in America (United States, Canada) and Europe indicate that control of hypertension is insufficient despite pharmacotherapy: hypertension control (ABP <140/90 mm Hg) varies from 8.3% to 42% in different countries (11-21). The data from other published trials indicate that the level of ABP control in treated patients is lower than in the mentioned trial. According to the data obtained from the WHO-MONICA study carried out in the city of Kaunas from 2001 to 2002, the proportion of 35–64-old men and women effectively treated with antihypertensive agents was 15.8% and 19.9%, respectively (22). The study conducted in 5 primary health care institutions of Vilnius city in the year 2005 showed that target ABP (<140/90 mm Hg) was achieved only in 5.8% of the examined patients who continuously used antihypertensive agents (23).

Almost 85% of the patients in this study were treated with a combination of two or more antihypertensive agents. A high proportion of patients who received combined treatment may nearly explain the high level of the controlled blood pressure seen in this study. However, despite of the fact that almost all high- and very high-risk patients (90.2%) were treated with a combination of drugs, the target ABP was achieved only by 26.3% of the patients from this group. One of the possible reasons may be the lower target ABP (<135/85–125/75 mm Hg) for high- and very high-risk patients, comparing with the target ABP (<140/90 mm Hg) for low- and moderate-risk patients. According to the data obtained from similar studies performed in other countries, monotherapy was used in 30%–60% of hypertension patients (13–19, 21, 24, 25). There are no data in Lithuania regarding the use of antihypertensive agents in publications about ABP control (22, 23). In case of monotherapy (even using maximum doses), blood pressure control is achieved in less than 50% of patients suffering from hypertension (26). Combinations of drugs are much more effective: in the hypertension treatment guidelines, low-dose combination therapy is indicated as a first-choice therapy in high- and very high-risk patients (9, 26, 27). Combinations of drugs are more effective in blood pressure control even for the patients who were unsuccessfully treated with different single drugs (28–31).

We have no information about how patients complied with instructions assigned by physicians (the continuous use of drugs, use of full prescribed doses, considering life style recommendations, etc.). The performed trials indicate that usually the patients are not strictly following treatment recommendations, and physicians indicate it as the main reason of insufficient blood pressure control (3).

Possibility of sampling errors (possibility of inclusion of patients with better controlled blood pressure) cannot be rejected when analyzing study results. To minimize sampling errors, every third patient who came for a regular visit was included into this clinical trial.

The comparison of the groups of the patients who achieved or did not achieve target ABP indicates that in the group of the patients who did not achieve target ABP, there were more patients who had several concomitant diseases or several risk factors. Patients who did not achieve target ABP were treated with a combination of two or more drugs more frequently; however, almost 12% of these patients were given monotherapy. For the patients who achieved target ABP, only nonpharmacologic measures were recommended more frequently, whereas for the patients who did not achieve target ABP, nonpharmacologic recommendations were usually combined with an increased dose of the used drugs or with administration of an additional drug. Physicians did not change the treatment for almost 16% of the patients who did not achieve target ABP.

**Conclusions**

The results of this study indicate that despite pharmacologic treatment, the level of arterial blood pressure control was not sufficient in the studied group of patients (45.4%), especially in the group of high- and very high-risk patients (26.3%). In addition, almost 12% of the patients with unachieved target arterial blood pressure were still undergoing monotherapy, whereas no modifications of antihypertensive treatment were given for 16% of the
Arterinės hipertenzijos kontrolės ir gydymo įvertinimas šeimos gydytojų kasdienėje praktikoje

Žaneta Petrunionienė 1,2, Daiva Asta Apanavičienė 3

1Vilniaus universiteto ligoninės Santarūšių klinikų Kardiologijos ir angiologijos centras,
2Vilniaus universiteto Širdies ir kraujagyslių ligų klinika, 3”Sanofi-Aventis Lietuva”

Raktąžodžiai: arterinė hipertenzija, kraujoispūdžio kontrolė, vaistai nuo hipertenzijos.

Santrauka. Tyrimo tikslas. Nustatyti, kokia dalis sarančių pirmine arterinė hipertenzija (PAH) ir vaisaitais nuo hipertenzijos gydomų pacientų pasiekės mažumą tikslinį arterinį kraujoispūdį (AKS) bei palyginti tikslinių AKS pasiektų ir nepasiektų pacientų charakteristikas, jiems skirtą gydymą bei rekomenduotas gydymo koregavimo priemones.

Tyrimo medžiaga ir metodai. Epidemiologiniame tyrime dalyvavo 429 18–80 metų pacientai, sergantys PAH, kuri gydoma ne trumpiai kaip vienerius metus. Šeimos gydytojai surinko informaciją apie pacientų demografinės ir klinikines charakteristikas, taikomą hipertenzijos gydymą bei rekomenduojamas gydymo koregavimo priemones.

Rezultatai. Gydytojų vertinimu, 45,4 proc. pacientų buvo pasiekti tikslinį AKS, mažos ir vidutinės širdies ir kraujagyslių ligų (ŠKL) rizikos grupėje tikslinių AKS pasieko 26 (12,5 proc.) pacientų (p<0,0001). Pagal tyrimo metu išmatuoto AKS rodmenis 160 (47,3 proc.) pacientų AKS buvo <140/90 mm Hg. Daugiausia pacientų vartojo didelės rizikos grupėje tikslinį AKS pasiekė 78 (36,3 proc.) pacientų, o didelės ir labai didelės rizikos grupėje tikslinį AKS pasiekė 141 (62,9 proc.) pacientas, o didelės ir labai didelės rizikos grupėje tikslinį AKS nebuvo pasiekę 69 (32,1 proc.) pacientų. Gydytojai nekeitė gydymo 22,7 proc. pacientų, didžiausiai tie pacientai, kurie pasieko tikslinį AKS.

Išvados. AKS kontrolė tirtių pacientų grupėje buvo nepakankama, ypač didelės ir labai didelės rizikos pacientų grupėje, kurioje nustatytas griežtesnis tikslinį AKS. Be to, beveik 12 proc. tikslinių AKS pasiektų pacientų, dažniausiai tiems, kurie pasieko tikslinį AKS, dažniau buvo gydomi tikslinio AKS nepasieke pacientai. Gydytoja i nekeitė gydymo 37,8 proc. (n=162) pacientų, dviejų (n=153, 35,7 proc.) arba trijų (n=144, 33,6 proc.) vaistų nuo hipertenzijos derinius. Vaistų deriniuose suaugu 160 (37,3 proc.) pacientų AKS buvo <140/90 mm Hg. Didiausia pacientų vartojo didelės rizikos grupėje tikslinį AKS pasiekė 141 (62,9 proc.) pacientas, o didelės ir labai didelės rizikos grupėje tikslinį AKS nebuvo pasiekę 69 (32,1 proc.) pacientų, o didelės ir labai didelės rizikos grupėje tikslinį AKS nebuvo pasiekę 69 (32,1 proc.) pacientų.

References
1. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;375:1571-6.
2. Klumbienė J, Petkevičienė J, Misevičienė I, Plieskienė A. Arterinės hipertenzijos paplitimas ir kontrolė pokyčiai 1987–1999 m. (The changes of arterial hypertension prevalence and its control in 1987–1999.) Lietuvos bendrosios praktikos gydytojas 2002;6:751-6.
3. Lindholm LH. The problem of uncontrolled hypertension. J Hum Hypertens 2002;16 Suppl 3:S3-8.
4. Sanson-Fisher RW, Clover K. Compliance in the treatment of hypertension: A need for action. Am J Hypertens 1995;8:825-8S.
5. Oliveira SA, Lapuerta P, McCarthy D, L’Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162:413-20.
6. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458-65.
7. Nelson MR, Reid CM, Krum H, McNeil JJ. Factors influencing family physician adherence to hypertension treatment guideline recommendations on the initiation of pharmacotherapy. Am J Cardiovasc Drugs 2003;3:437-41.
8. Vaškelienė V, Babarskienė MR, Macijauskiénė J, Šekevičius A. Arterinės hipertenzijos trukmės ir gydymo įtaka su sveikata susijusiai gyvenimo kokybei. (Impact of duration and treatment of arterial hypertension on health-related quality of life.) Medicina (Kaunas) 2009;45(5):403-11.
9. Arterinės hipertenzijos, hipertenzinės širdies ir inkstų ligų (ICD codes I10-I13, I15) diagnostikos bei ambulato rio gydymo, kompensuojamo iš privalomojo sveikatos draudimo fondo biudžeto lėšų, metodika. (Guidelines on diagnostics and treatment of essential hypertension, hypertensive heart and renal diseases [ICD codes I10-I13, I15].) Žin 2003;58:2624.
10. European Society of Hypertension-European Society of Cardiology Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53.
11. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and...
control in five European countries, Canada, and the United States. Hypertension 2004;43:10-7.
12. Vitežić D, Burke T, Mrsić-Pelčić J, Mavrić Z, Zaputović I, Zupan G, et al. Characteristics of blood-pressure control in treated hypertensive patients in Croatia. Blood Press Suppl 2005;2:33-41.
13. Gryzbowski A, Bellwon J, Gruchala M, Stolarczyk L, Popaszkiewicz J, Sobiczewski W, et al. Effectiveness of hypertension treatment assessed by blood pressure level achieved in primary care setting in Poland. Blood Press 2003;12:232-8.
14. Avanzini F, Ali C, Colombo P, Corsetti A, Colombo F, Tognoni G. Control of hypertension in Italy: results of the “Study on Antihypertensive Treatment in General Practice (STAP)”. Physicians Taking Part in STAP. G Ital Cardiol 1998;28:760-6.
15. Westheim A, Klemetsrud T, Tretli S, Stokke HP, Olsen H. Blood pressure levels in treated hypertensive patients in general practice in Norway. Blood Press 2001;10:37-42.
16. Hedblad B, Nerbrand C, Ekesbo R, Johansson L, Midlöv P, Brunkstedt I, et al. High blood pressure despite treatment: results from a cross-sectional primary healthcare-based study in southern Sweden. Scand J Prim Health Care 2006;24:224-30.
17. Banegas JR, Segura J, Ruilope LM, Luque M, Garcia-Robles R, Campo C, et al. Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. Hypertension 2004;43:1338-44.
18. Primastesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2003;38:827-32.
19. Mallion JM, Genèis N, Vaur L, Clerson P, Vaisse B, Bobrie G, et al. Blood pressure levels, risk factors and antihypertensive treatments: lessons from the SHEAF study. J Hum Hypertens 2001;15:841-8.
20. Mancia G, Bombelli M, Lanzarotti A, Grassi G, Cesana G, Zanchetti A, et al. Systolic vs diastolic blood pressure control in the hypertensive patients of the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Arch Intern Med 2002;162:582-6.
21. Fagard RH, Van Den Enden M, Leeman M, Warling X. Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium. J Hypertens 2002;20:1297-302.
22. Jurieniè K, Tamošiūnas A, Domarkienè S. Control of hypertension during 10 years period in Lithuanian middle-aged population. World Hypertension League. Community Control of Hypertension with Special Emphasis on Central and Eastern Europe. Prague Meeting, April 24, 2004.
23. Simanauskas K, Kasulevičius V. Kardiovaskulišių rizikos veiksnių paplitimas ir kraujospūdžio kontrolė tarp amžiaus lignonų Vilniaus mieste. (The prevalence of cardiovascular risk factors and blood pressure control among elderly patients in Vilnius city.) Gerontologija 2007;8:212-6.
24. Psaty BM, Manolio TA, Smith NL, Heckbert SR, Gottdiner JS, Burke GL, et al. Time trends in high blood pressure control and the use of antihypertensive medications in older adults: the Cardiovascular Health Study. Arch Intern Med 2002;162:2325-32.
25. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007;167:141-7.
26. Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007;16(3):135-232.
27. Prisant LM, Weir MR, Papademetriou V, Weber MA, Adgbile IA, Alemayehu D, et al. Low-dose drug combination therapy: an alternative first-line approach to hypertension treatment. Am Heart J 1995;130:359-66.
28. Materson BJ, Reda DJ, Cushman WC, Henderson WG. Results of combination anti-hypertensive therapy after failure of each of the components. Department of Veterans Affairs Cooperative Study Group on Anti-hypertensive Agents. J Hum Hypertens 1995;9:791-6.
29. Dollery CT. Pharmacological basis for combination therapy of hypertension. Ann Rev Pharmacol Toxicol 1997;17:311-23.
30. Oster JR, Epstein M. Fixed-dose combination medications for the treatment of hypertension: a critical review. J Clin Hypertens 1987;3:278-93.

Received 2 November 2009, accepted 5 October 2010